Checkpoint inhibitor

BeyondSpring Presents Phase 1 Data on the Anti-Cancer Effect of Plinabulin in Combination with Checkpoint Inhibitors in SCLC at the American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, May 24, 2021
Clinical medicine, Cancer treatments, Drugs, Lung cancer, Bristol-Myers Squibb, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Ipilimumab, Nivolumab, Small-cell carcinoma, Checkpoint inhibitor

The poster, titled A Phase I Trial of Plinabulin in Combination with Nivolumab and Ipilimumab in Patients with Recurrent Small Cell Lung Cancer (SCLC), will be presented at 9 a.m.

Key Points: 
  • The poster, titled A Phase I Trial of Plinabulin in Combination with Nivolumab and Ipilimumab in Patients with Recurrent Small Cell Lung Cancer (SCLC), will be presented at 9 a.m.
  • ORR was 50% for the six patients receiving the triple IO combination as second line therapy after platinum.
  • SCLC still represents an area of tremendous unmet medical need.This study supports the hypothesisthat theaddition ofplinabulin toanivolumab+ipilimumabregimen could increaseresponse ratesin 2nd/3rd line SCLC.
  • The study is small,but some patients who previously developed resistance to checkpoint inhibitors had durable responses and large tumor reduction.

Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 21, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Clinical medicine, Medicine, Bladder cancer, Carcinogenesis, Oportuzumab monatox, Epithelial cell adhesion molecule, Cancer immunotherapy, Cancer cell, Checkpoint inhibitor, Oncology, Vicineum™, Sesen Bio, VICINEUM™, SESEN BIO

The option was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).\nVicineum, a locally administered fusion protein, is Sesen Bio\xe2\x80\x99s lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • The option was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).\nVicineum, a locally administered fusion protein, is Sesen Bio\xe2\x80\x99s lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
  • In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells.
  • Sesen Bio is currently in the follow-up stage of a Phase 3 registration trial in the US for the treatment of BCG-unresponsive NMIBC.
  • Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors.

TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting

Retrieved on: 
Thursday, May 20, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Medical specialties, Bristol-Myers Squibb, Checkpoint inhibitor, Immune system, Ipilimumab, Microsatellite instability

b"The posters will be available on the publications page of the company\xe2\x80\x99s website following presentation.\nEnvafolimab (KN035), a novel, single-domain antibody against PD-L1, is the first subcutaneously injected PD-(L)1 inhibitor to be studied in pivotal trials.

Key Points: 
  • b"The posters will be available on the publications page of the company\xe2\x80\x99s website following presentation.\nEnvafolimab (KN035), a novel, single-domain antibody against PD-L1, is the first subcutaneously injected PD-(L)1 inhibitor to be studied in pivotal trials.
  • TRACON\xe2\x80\x99s partners Alphamab Oncology and 3D Medicines submitted an NDA to the NMPA in China for envafolimab in MSI-H/dMMR cancer that was accepted for review in December 2020 and granted priority review in January 2021.
  • TRACON expects the trial to enroll 160 patients with UPS or MFS who have progressed following one or two lines of prior treatment and have not received an immune checkpoint inhibitor, with 80 patients enrolled into cohort A of treatment with single agent envafolimab and 80 patients enrolled in cohort B of treatment with envafolimab and Yervoy.
  • TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization.\xc2\xa0 In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.\xc2\xa0 To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com .\n"

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

Retrieved on: 
Thursday, May 20, 2021
Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Checkpoint inhibitor, Immune system, Pelareorep, Asco, Oncology, Cancer

(NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer.
  • I look forward to discussing these data with the scientific community at the upcoming ASCO conference and to the continued evaluation of pelareorep-checkpoint inhibitor combination therapy in select patients with pancreatic and other gastrointestinal cancers.
  • "\nThe data presented in the upcoming ASCO poster represent an update based on additional data that was collected after the cutoff date used for the poster\'s corresponding abstract.
  • This positions pelareorep to synergistically combine with both checkpoint inhibitors as well as a broad range of other immuno-oncology agents.

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

Retrieved on: 
Thursday, May 20, 2021
Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Checkpoint inhibitor, Immune system, Pelareorep, Asco, Oncology, Cancer

(NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer.
  • I look forward to discussing these data with the scientific community at the upcoming ASCO conference and to the continued evaluation of pelareorep-checkpoint inhibitor combination therapy in select patients with pancreatic and other gastrointestinal cancers.
  • "\nThe data presented in the upcoming ASCO poster represent an update based on additional data that was collected after the cutoff date used for the poster\'s corresponding abstract.
  • This positions pelareorep to synergistically combine with both checkpoint inhibitors as well as a broad range of other immuno-oncology agents.

Ultimovacs’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data

Retrieved on: 
Wednesday, May 19, 2021
Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Pembrolizumab, Checkpoint inhibitor, Immunotherapy, Melanoma

The median progression-free survival for the UV1/pembrolizumab combination in the study was 18.9 months compared with 5.5-11.6 months* for pembrolizumab alone in advanced melanoma.

Key Points: 
  • The median progression-free survival for the UV1/pembrolizumab combination in the study was 18.9 months compared with 5.5-11.6 months* for pembrolizumab alone in advanced melanoma.
  • \xe2\x80\x9cIt suggests that UV1 in combination with checkpoint inhibitors like pembrolizumab can mobilize the immune system to fight cancer.
  • The clinical development of the UV1 vaccine includes four randomized, multinational, Phase II combination trials: INITIUM, NIPU, DOVACC and FOCUS, recruiting over 500 patients in total.
  • Ultimovacs\xe2\x80\x99 strategy is to clinically demonstrate UV1\xe2\x80\x99s impact in many cancer types and in combination with other immunotherapies.

SQZ Biotechnologies to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors

Retrieved on: 
Wednesday, May 19, 2021
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer, Clinical medicine, Medicine, Papillomavirus, Infectious causes of cancer, Carcinogenesis, Carcinogens, Human papillomavirus infection, Checkpoint inhibitor, Cancer immunotherapy, Human Papillomavirus Positive Cancers, SQZ Biotechnologies, HUMAN PAPILLOMAVIRUS POSITIVE CANCERS, SQZ BIOTECHNOLOGIES

In the next stage of the trial, it is planned to combine SQZ-PBMC-HPV-101 with immune checkpoint inhibitors.

Key Points: 
  • In the next stage of the trial, it is planned to combine SQZ-PBMC-HPV-101 with immune checkpoint inhibitors.
  • The study\xe2\x80\x99s primary outcome measures in the monotherapy stage of the trial are safety, tolerability, and the definition of the recommended phase 2 dose.
  • The investigational candidate, which targets E6 and E7 oncoproteins, is being studied as a monotherapy and in combination with immuno-oncology agents.
  • The planned safety combination phase of the study will include SQZ-PBMC-HPV-101 and checkpoint inhibitors that have previously received regulatory approval.

Alpine Immune Sciences To Host Investor Event at 2021 ASCO Virtual Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Cancer immunotherapy, Immune system, Virotherapy, Checkpoint inhibitor, Immunotherapy, Application-Layer Protocol Negotiation, Computing, Telecommunications, ALPN-202, Alpine Immune Sciences, Inc., ALPN-202, ALPINE IMMUNE SCIENCES, INC.

b'Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Alpine will hold an investor event on June 4th, 2021 at 7:00pm ET, to coincide with the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting.\nDuring the investor event, Alpine will present data from the previously announced presentation on NEON-1, the company\xe2\x80\x99s Phase 1 dose escalation clinical trial of ALPN-202 monotherapy, from the ASCO Virtual Annual Meeting (\xe2\x80\x9cFirst-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies\xe2\x80\x9d).

Key Points: 
  • b'Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Alpine will hold an investor event on June 4th, 2021 at 7:00pm ET, to coincide with the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting.\nDuring the investor event, Alpine will present data from the previously announced presentation on NEON-1, the company\xe2\x80\x99s Phase 1 dose escalation clinical trial of ALPN-202 monotherapy, from the ASCO Virtual Annual Meeting (\xe2\x80\x9cFirst-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies\xe2\x80\x9d).
  • Preclinical studies of ALPN-202 have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone.
  • Alpine also plans the initiation of NEON-2, a combination study of ALPN-202 and a PD-1 inhibitor, later this year.\nAlpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics.
  • Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.

OncXerna Therapeutics to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Angiology, Medical specialties, Clinical medicine, Growth factors, Vascular endothelial growth factor, Angiogenesis, Checkpoint inhibitor, Bavituximab

b'WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.\nThe live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m.

Key Points: 
  • b'WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.\nThe live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m.
  • This allows OncXerna to pair those patients with OncXerna\xe2\x80\x99s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • OncXerna\xe2\x80\x99s clinical trials currently combine bavituximab with KEYTRUDA\xc2\xae to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors.

Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic Melanoma

Retrieved on: 
Wednesday, May 12, 2021
Clinical medicine, Medicine, Cancer treatments, Breakthrough therapy, Orphan drugs, Cancer immunotherapy, Lung cancer, Antineoplastic drugs, Melanoma, Checkpoint inhibitor, Non-small-cell lung carcinoma, Nivolumab

Lifileucel represents a significant improvement in the treatment of advanced melanoma, particularly in the expanding post-immune checkpoint inhibitor patient population.

Key Points: 
  • Lifileucel represents a significant improvement in the treatment of advanced melanoma, particularly in the expanding post-immune checkpoint inhibitor patient population.
  • As a reference, patients treated with chemotherapy are expected to have an OS of approximately 7 months.
  • The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer.
  • In addition, the company\xe2\x80\x99s TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC).